 Terazosin pharmacokinetics effect age incidence adverse events Terazosin new long-acting selective postsynaptic receptor antagonist chemical structure similar prazosin article pharmacokinetics terazosin incidence adverse events dose-response study meta-analysis placebo-controlled trials total patients Peak plasma concentrations terazosin hours oral administration long half-life terazosin hours once-a-day regimen Dose plasma levels terazosin linear relationship Terazosin oral administration pharmacokinetics terazosin food age hypertension renal impairment Adverse events administration terazosin minor age incidence syncope therapeutic dosages terazosin minimal Terazosin effectiveness pharmacokinetics safety profile favorable lipid effect appropriate choice antihypertensive therapy